Cargando…

Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data

Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to restore an anti-tumor immune response of T cells. Pembrolizumab is one of the most advanced immune checkpoint inhibitors for canc...

Descripción completa

Detalles Bibliográficos
Autores principales:	du Rusquec, Pauline, de Calbiac, Ombline, Robert, Marie, Campone, Mario, Frenel, Jean Sebastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527794/ https://www.ncbi.nlm.nih.gov/pubmed/31190995 http://dx.doi.org/10.2147/CMAR.S151023

Ejemplares similares

Targeting the PI3K/Akt/mTOR pathway in estrogen-receptor positive HER2 negative advanced breast cancer
por: du Rusquec, Pauline, et al.
Publicado: (2020)

Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors
por: Alcantara, Marion, et al.
Publicado: (2020)

Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes
por: Billaud, Amandine, et al.
Publicado: (2021)

The predictive value of patient-reported outcomes on the impact of breast cancer treatment-related quality of life
por: Zhou, Ke, et al.
Publicado: (2022)

2568 Pembrolizumab for patients with leptomeningeal disease from advanced solid tumors
por: Naidoo, Jarushka, et al.
Publicado: (2018)

Partial tumor irradiation plus pembrolizumab in treating large advanced solid tumor metastases
por: Korpics, Mark C., et al.
Publicado: (2023)

Optimizing the Retrieval of the Vital Status of Cancer Patients for Health Data Warehouses by Using Open Government Data in France
por: Lauzanne, Olivier, et al.
Publicado: (2022)

Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers
por: Bocquet, François, et al.
Publicado: (2023)

Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy
por: Augereau, Paule, et al.
Publicado: (2017)

Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors
por: Rahma, Osama E, et al.
Publicado: (2022)

Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors
por: Luke, Jason J., et al.
Publicado: (2023)

The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
por: Colombié, Mathilde, et al.
Publicado: (2021)

Immunogenicity of pembrolizumab in patients with advanced tumors
por: van Vugt, Marianne J. H., et al.
Publicado: (2019)

bc-GenExMiner 3.0: new mining module computes breast cancer gene expression correlation analyses
por: Jézéquel, Pascal, et al.
Publicado: (2013)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients
por: Moreau-Bachelard, Camille, et al.
Publicado: (2020)

Impact of HER2 Status on Pathological Response after Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer
por: Domergue, Camille, et al.
Publicado: (2022)

Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors
por: Park, H., et al.
Publicado: (2022)

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Drug Development in Tissue-Agnostic Indications
por: du Rusquec, Pauline, et al.
Publicado: (2021)

Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
por: Hurkmans, Daan P., et al.
Publicado: (2021)

Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types
por: Cristescu, Razvan, et al.
Publicado: (2022)

Risks and benefits of anticancer drugs in advanced cancer patients: A systematic review and meta-analysis
por: Moreau Bachelard, Camille, et al.
Publicado: (2021)

Phase 1 dose escalation study of FGFR4 inhibitor in combination with pembrolizumab in advanced solid tumors patients
por: Xu, Jianming, et al.
Publicado: (2023)

Pembrolizumab Utilization and Outcomes for Advanced Melanoma in US Community Oncology Practices
por: Cowey, C. Lance, et al.
Publicado: (2018)

Anti-PD1 therapy induces lymphocyte-derived exosomal miRNA-4315 release inhibiting Bim-mediated apoptosis of tumor cells
por: Guyon, Nina, et al.
Publicado: (2020)

Model‐Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti–PD‐1 Monoclonal Antibody in Advanced Solid Tumors
por: Ahamadi, M, et al.
Publicado: (2016)

Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
por: Fiorelli, Alfonso, et al.
Publicado: (2019)

Impact of the timing of tumor assessments on median progression-free survival in clinical trials in advanced cancer patients
por: Samaille, T., et al.
Publicado: (2021)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors
por: Razak, Albiruni RA, et al.
Publicado: (2020)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
por: Johnson, Melissa, et al.
Publicado: (2022)

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
por: Taylor, Matthew H., et al.
Publicado: (2020)

Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours
por: Fumoleau, Pierre, et al.
Publicado: (2013)

Relationship between immune gene signatures and clinical response to PD-1 blockade with pembrolizumab (MK-3475) in patients with advanced solid tumors
por: Ayers, Mark, et al.
Publicado: (2015)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

Epacadostat Plus Pembrolizumab and Chemotherapy for Advanced Solid Tumors: Results from the Phase I/II ECHO-207/KEYNOTE-723 Study
por: Powderly, John D, et al.
Publicado: (2022)

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
por: Naidoo, Jarushka, et al.
Publicado: (2021)

Time to Treatment With Nivolumab or Pembrolizumab for Patients With Advanced Melanoma in Everyday Practice
por: Ksienski, Doran, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors
por: Någård, Mats, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0n3tkh3k5sl1diifusoiarfcno